Showing results (221-230 of 355) with videos related to

Sort By:
Pageof 36
JACC. Heart Failure|February 5, 2026
Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HFMisato Chimura, Alasdair D Henderson, Pardeep S Jhund, et al.
The Journal of Infection|September 20, 2024
Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: A post hoc analysis of the DANFLU-1 randomized clinical trialJacob Christensen, Niklas Dyrby Johansen, Kira Hyldekær Janstrup, et al.
Circulation|October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER TrialJohn W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
European Journal of Heart Failure|February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trialJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
American Heart Journal|May 23, 2023
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVERAnkeet S Bhatt, Daniel Lindholm, Ann Nilsson, et al.
European Journal of Heart Failure|May 21, 2023
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HFSafia Chatur, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection FractionSara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
The Lancet. Diabetes & Endocrinology|November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trialSilvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
JACC. Heart Failure|May 25, 2023
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Jorge Thierer, Brian L Claggett, et al.
Pageof 36